# Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study

> **NCT00863005** · PHASE1,PHASE2 · COMPLETED · sponsor: **Moberg Pharma AB**

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** K201
- **DRUG:** K201

## Key facts

- **NCT ID:** NCT00863005
- **Lead sponsor:** Moberg Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863005, "Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00863005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*